The Effect of A100 Gel, on Hair Growth and Hair Quality: An Explanatory Study

Full-Text HTML XML Download Download as PDF (Size:348KB) PP. 19-23
DOI: 10.4236/jcdsa.2016.61003    2,594 Downloads   7,361 Views  

ABSTRACT

Male pattern baldness or androgenic alopecia is a great problem for many individuals’ especially young people. A100 is composed of two active ingredients, a pollen extract and pentane-1,5-diol. The pollen extract provides a source of natural nutrients and pentane-1,5-diol acts as a solvent to unplug the hair follicle as well as acts as an enhancer for uptake of nutrients. Other components are claimed to increase blood flow to the hair papilla. A100 has been effective in earlier studies. The aim of this open explanatory study was to investigate the effect of 4 months twice daily application with this commercial pollen gel, A100, in subjects with male androgenic alopecia. Twenty male subjects, between 18 and 40 years with androgenic alopecia were included. A100 gel was applied to the area of the scalp with poor hair growth twice daily for 4 months. The subjects were seen at the start of treatment and then every month. Sixteen subjects fulfilled the whole 4 months of treatment and 2 fulfilled 3 months of treatment. A statistically significant increase in number of hairs was seen after 4 months of treatment with A100 (p < 0.001). This effect was seen for all types of hair. Fifty-six percent of the 16 subjects who fulfilled the 4 months treatment had an increase in hair growth of more than 50%, and 31% had an increase over 100%. No side effects were seen and the subjects found A100 gel a cosmetically attractive treatment. A100 was in this explanatory study an effective and safe treatment for androgenic alopecia or male pattern baldness.

Cite this paper

Faergemann, J. and Hedner, T. (2016) The Effect of A100 Gel, on Hair Growth and Hair Quality: An Explanatory Study. Journal of Cosmetics, Dermatological Sciences and Applications, 6, 19-23. doi: 10.4236/jcdsa.2016.61003.

References

[1] Dawber, R.P.R., de Berker, D. and Wojnarowska, F. (1998) Alopecia Ch 66, Disorders of Hair. In Rook/Wilkinsson/ Ebling, Eds. In: Champion, R.H., Burton, J.L., Burns, D.A. and Breathnach, S.M., Eds., Textbook of Dermatology, Vol. 4, 6th Edition, Blackwell Science Publ., Oxford, 2903-2909.
[2] Rushton, D.H. (1999) Androgenetic Alopecia in Men: The Scale of the Problem and Prospects for Treatment. International Journal of Clinical Practice, 53, 50-53.
[3] Hamilton, J.B. (1951) Patterned Loss of Hair in Man: Types and Incidence. American Journal of New York Academy of Sciences, 53, 708-728.
http://dx.doi.org/10.1111/j.1749-6632.1951.tb31971.x
[4] Koperski, J.A., Orenberg, E.K. and Wilkinson, D.I. (1987) Topical Minoxidil Therapy for Androgenetic Alopecia. Archives of Dermatology, 123, 1483-1487.
http://dx.doi.org/10.1001/archderm.1987.01660350083018
[5] Rietschel, R.L. and Duncan, S.H. (1987) Safety and Efficacy of Topical Minoxidil in the Management of Androgenetic Alopecia. Journal of the American Academy of Dermatology, 16, 677-685.
http://dx.doi.org/10.1016/S0190-9622(87)70087-5
[6] Finasteride Male Pattern Hair Loss Study Group (2002) Long-Term (5-Year) Multinational Experience with Finasteride 1 mg in the Treatment of Men with Androgenetic Alopecia. European Journal of Dermatology, 12, 38-49.
[7] Whiting, D.A., Olsen, E.A., Savin, R., Halper, L., Rodgers, A., Wang, L., Hustad, C. and Palmisano, D. (2002) Efficacy and Tolerability of Finasteride 1 mg in Men Aged 41 to 60 Years with Male Pattern Hair Loss. European Journal of Dermatology, 13, 150-160.
[8] Altomare, G. and Capella, G.L. (2002) Depression Circumstantially Related to the Administration of Finasteride in Androgenic Alopecia. Journal of Dermatology, 29, 665-669.
http://dx.doi.org/10.1111/j.1346-8138.2002.tb00200.x
[9] Sundberg, J.J. and Faergemann, J. (2008) A Comparison of Pentane-1,5-Diol to Other Diols for Use in Dermatology. Expert Opinion for Investigative Drugs, 17, 601-610.
http://dx.doi.org/10.1517/13543784.17.4.601

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.